Literature DB >> 25997819

MicroRNA-29a inhibits cell migration and invasion via targeting Roundabout homolog 1 in gastric cancer cells.

Xueting Liu1, Jun Cai2, Yanjun Sun2, Renhua Gong2, Dengqun Sun2, Xingguo Zhong2, Shitao Jiang2, Xinmiao He2, Enwu Bao2, Liusheng Yang2, Yongxiang Li1.   

Abstract

Deregulation of Roundabout homolog 1 (Robo1) has been demonstrated to be associated with several types of human cancer, including gastric cancer. However, the detailed role of Robo1 and its regulatory mechanism in gastric cancer remain largely unclear. In the current study, it was demonstrated that the expression of microRNA (miR)‑29a was frequently reduced in gastric cancer tissues, compared with their matched normal adjacent tissues. Similar results were additionally observed in AGS and SGC‑7901 human gastric cancer cells. Overexpression of miR‑29a led to reduced migration and invasion of AGS cells. To explore the targets of miR‑29a in gastric cancer, bioinformatics analysis was conducted and Robo1 was identified as a putative target of miR‑29a. Further western blotting and luciferase activity assay data confirmed that miR‑29a was able to negatively regulate the protein expression of Robo1, through directly binding to the 3'‑untranslated region of Robo1 mRNA in gastric cancer cells. In addition, it was demonstrated that Robo1 was frequently upregulated in gastric cancer tissues compared with their matched adjacent normal tissues, and a significant inverse correlation was identified between miR‑29a and Robo1 expression. In addition, knockdown of Robo1 by small interfering RNA markedly inhibited the migratory and invasive capabilities of AGS cells, which the results obtained with overexpression of miR‑29a. In conclusion, to the best of our knowledge the current study suggested for the first time, that miR‑29a inhibits migration and invasion in part via direct inhibition of Robo1 in gastric cancer cells. Therefore, Robo1 and miR‑29a may serve as diagnostic or therapeutic targets for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25997819     DOI: 10.3892/mmr.2015.3817

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer.

Authors:  Yongqiang Li; Zhi Wang; Yijiang Li; Ruijun Jing
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

2.  Long non-coding RNA LINC00473 acts as a microRNA-29a-3p sponge to promote hepatocellular carcinoma development by activating Robo1-dependent PI3K/AKT/mTOR signaling pathway.

Authors:  Qiqin Song; Hongyue Zhang; Jinan He; Hongyan Kong; Ran Tao; Yu Huang; Haijing Yu; Zhongwei Zhang; Zhiyong Huang; Lai Wei; Chenghai Liu; Likui Wang; Qin Ning; Jiaquan Huang
Journal:  Ther Adv Med Oncol       Date:  2020-08-27       Impact factor: 8.168

3.  Inhibition of microRNA‑939 suppresses the development of human non‑small cell lung cancer via the upregulation of tissue inhibitor of metalloproteinases 2.

Authors:  Aidong Chen; Shengping Liu; Xiaohu Lu; Lei Wei; Yijiang Chen
Journal:  Mol Med Rep       Date:  2018-09-20       Impact factor: 2.952

4.  Downregulation of the human peripheral myelin protein 22 gene by miR-29a in cellular models of Charcot-Marie-Tooth disease.

Authors:  Jacquelyn Serfecz; Hannah Bazick; Mohammed Omar Al Salihi; Peter Turner; Christopher Fields; Pedro Cruz; Rolf Renne; Lucia Notterpek
Journal:  Gene Ther       Date:  2019-08-27       Impact factor: 5.250

Review 5.  Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals.

Authors:  Seung Wan Son; Han Yeoung Lee; Sokviseth Moeng; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

6.  miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.

Authors:  Xiaoyun Yang; Yurong Liang; Gayan Bamunuarachchi; Yanzhao Xu; Kishore Vaddadi; Samuel Pushparaj; Dao Xu; Zhengyu Zhu; Rachel Blaha; Chaoqun Huang; Lin Liu
Journal:  Arch Virol       Date:  2020-11-18       Impact factor: 2.574

7.  Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Michelle R Huyser; Li Yan; Masahiro Fukada; Nobuhisa Matsuhashi; Manabu Futamura; Yukihiro Akao; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

8.  miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma.

Authors:  Xiao Wang; Shasha Liu; Ling Cao; Tengfei Zhang; Dongli Yue; Liping Wang; Yu Ping; Qianyi He; Chaoqi Zhang; Meng Wang; Xinfeng Chen; Qun Gao; Dan Wang; Zhen Zhang; Fei Wang; Li Yang; Jieyao Li; Lan Huang; Bin Zhang; Yi Zhang
Journal:  Oncotarget       Date:  2017-09-23

Review 9.  MiR-29a: a potential therapeutic target and promising biomarker in tumors.

Authors:  Jin-Yan Wang; Qian Zhang; Dan-Dan Wang; Wei Yan; Huan-Huan Sha; Jian-Hua Zhao; Su-Jin Yang; He-da Zhang; Jun-Chen Hou; Han-Zi Xu; Yun-Jie He; Jia-Hua Hu; Shan-Liang Zhong; Jin-Hai Tang
Journal:  Biosci Rep       Date:  2018-02-08       Impact factor: 3.840

10.  Conserved temporal ordering of promoter activation implicates common mechanisms governing the immediate early response across cell types and stimuli.

Authors:  Annalaura Vacca; Masayoshi Itoh; Hideya Kawaji; Erik Arner; Timo Lassmann; Carsten O Daub; Piero Carninci; Alistair R R Forrest; Yoshihide Hayashizaki; Stuart Aitken; Colin A Semple
Journal:  Open Biol       Date:  2018-08       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.